Philogen (PHIL) Q1 2026 earnings summary

Executive summary

• Ended Q1 2026 with a positive net financial position of €355.4 million, down 3.5% from December 31, 2025.

• Cash and cash equivalents totaled €366.1 million, a 3.4% decrease from year-end 2025, mainly due to operating costs, capital expenditures, treasury share purchases, and financial operations.

• Industrial programs are progressing as planned, with no significant changes to previously communicated timelines.

Financial highlights

• Net financial debt decreased to €355.4 million as of March 31, 2026, from €368.3 million at year-end 2025.

• Cash and cash equivalents declined by €13.1 million, primarily due to €9.4 million in operating costs and €4.4 million in net negative financial operations.

• Current and non-current financial debt decreased by 2.1% to €10.7 million, consisting solely of lease liabilities.

Outlook and guidance

• Industrial programs, including key clinical trials, are proceeding according to expected methods and timelines, with encouraging results.